Advertisement
Journal of Hepatology
EASL
Advanced searchSave search
Editorial| Volume 68, ISSUE 4, P640-642, April 2018

Download started.

Ok

Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?

  • Christopher D. Byrne
    Correspondence
    Corresponding author. Address: Nutrition and Metabolism, Faculty of Medicine, Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital. Southampton SO16 6YD, UK.
    Affiliations
    Nutrition and Metabolism, Faculty of Medicine, Institute of Developmental Sciences (IDS), MP887, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK

    Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK
    Search for articles by this author
  • Gianluca Perseghin
    Affiliations
    Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy

    Department of Medicine and Rehabilitation, Unit of Metabolic Medicine, Policlinico di Monza, Monza, Italy
    Search for articles by this author
Published:December 10, 2017DOI:https://doi.org/10.1016/j.jhep.2017.12.002
Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?
Previous ArticleThe Egyptian hepatitis C programme: A model of HCV treatment intervention?
Next ArticlePyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications
      There is mounting evidence that besides increasing the risk of cirrhosis, end-stage liver disease and hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD) also affects risk of disease in organs beyond the liver.
      • Byrne C.D.
      • Targher G.
      NAFLD: A multisystem disease.
      J Hepatol. 2015; 62: S47-S64
      For example, NAFLD is an independent risk factor for cardiovascular disease (CVD),
      • Targher G.
      • Byrne C.D.
      • Lonardo A.
      • Zoppini G.
      • Barbui C.
      Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
      J Hepatol. 2016; 65: 589-600
      type 2 diabetes
      • Mantovani A.
      • Byrne C.D.
      • Bonora E.
      • Targher G.
      Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis.
      Diabetes Care. 2018; 41: 1-11
      and chronic kidney disease,
      • Mantovani A.
      • Zaza G.
      • Byrne C.D.
      • Lonardo A.
      • Zoppini G.
      • Bonora E.
      • et al.
      Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.
      Metabolism. 2017; ([Epub ahead of print])https://doi.org/10.1016/j.metabol.2017.11.003
      and NAFLD also increases risk of cardiac arrhythmias and aortic valve disease.
      • Byrne C.D.
      • Targher G.
      NAFLD: A multisystem disease.
      J Hepatol. 2015; 62: S47-S64
      However, whether NAFLD is a risk factor for impaired myocardial function is uncertain.

      Linked Article

      • Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients
        Journal of HepatologyVol. 68Issue 4
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) has become a common metabolic liver disease worldwide, with an estimated prevalence ranging from 25% to 45% in Asian as well as Western countries.1,2 NAFLD is defined as accumulation of lipids, mainly triglycerides, in ≥5% of hepatocytes with no evidence of excessive alcohol consumption or other secondary causes.3 The NAFLD spectrum ranges from simple steatosis, a benign disease with absence of hepatic inflammation and fibrosis, to non-alcoholic steatohepatitis (NASH), an aggressive condition that can develop into cirrhosis, hepatocellular carcinoma, and liver-related mortality.
        • Full-Text
        • PDF
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Byrne C.D.
        • Targher G.
        NAFLD: A multisystem disease.
        J Hepatol. 2015; 62: S47-S64
        View in Article
        • Targher G.
        • Byrne C.D.
        • Lonardo A.
        • Zoppini G.
        • Barbui C.
        Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
        J Hepatol. 2016; 65: 589-600
        View in Article
        • Mantovani A.
        • Byrne C.D.
        • Bonora E.
        • Targher G.
        Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis.
        Diabetes Care. 2018; 41: 1-11
        View in Article
        • Mantovani A.
        • Zaza G.
        • Byrne C.D.
        • Lonardo A.
        • Zoppini G.
        • Bonora E.
        • et al.
        Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.
        Metabolism. 2017; ([Epub ahead of print])https://doi.org/10.1016/j.metabol.2017.11.003
        View in Article
        • Lee Y.H.
        • Kim K.J.
        • Yoo M.E.
        • Kim G.
        • Yoon H.J.
        • Jo K.
        • et al.
        Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic individuals.
        J Hepatol. 2018; 68: 764-772https://doi.org/10.1016/j.jhep.2017.11.023
        View in Article
        • Wild S.H.
        • Morling J.R.
        • McAllister D.A.
        • Kerssens J.
        • Fischbacher C.
        • Parkes J.
        • et al.
        Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.
        J Hepatol. 2016; 64 ([Epub 2016 Jan 23]): 1358-1364https://doi.org/10.1016/j.jhep.2016.01.014
        View in Article
        • Wild S.H.
        • Walker J.J.
        • Morling J.R.
        • McAllister D.A.
        • Colhoun H.M.
        • Farran B.
        • et al.
        Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission.
        Diabetes Care. 2017; ([Epub ahead of print])https://doi.org/10.2337/dc17-1590
        View in Article
        • Sato M.
        • Kamada Y.
        • Takeda Y.
        • Kida S.
        • Ohara Y.
        • Fujii H.
        • et al.
        Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.
        Liver Int. 2015; 35: 925-935
        View in Article
        • Chang W.T.
        • Tsai W.C.
        • Wu C.H.
        • Lee Y.W.
        • Tai Y.L.
        • Li Y.H.
        • et al.
        Fetuin-A as a predicator of sarcopenic left ventricular dysfunction.
        Sci Rep. 2015; 5: 12078
        View in Article
        • Sung K.C.
        • Ryu S.
        • Kim B.S.
        • Cheong E.S.
        • Park D.I.
        • Kim B.I.
        • et al.
        Gamma-glutamyl transferase is associated with mortality outcomes independently of fatty liver.
        Clin Chem. 2015; 61: 1173-1181
        View in Article
        • Szendroedi J.
        • Chmelik M.
        • Schmid A.I.
        • Nowotny P.
        • Brehm A.
        • Krssak M.
        • et al.
        Abnormal hepatic energy homeostasis in type 2 diabetes.
        Hepatology. 2009; 50: 1079-1086
        View in Article
        • Perseghin G.
        • Lattuada G.
        • De Cobelli F.
        • Esposito A.
        • Belloni E.
        • Ntali G.
        • et al.
        Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver.
        Hepatology. 2008; 47: 51-58
        View in Article
        • Day S.M.
        The ubiquitin proteasome system in human cardiomyopathies and heart failure.
        Am J Physiol Heart Circ Physiol. 2013; 304: H1283-H1293
        View in Article
        • Scorletti E.
        • Byrne C.D.
        Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2-diabetes and dysbiosis.
        Dig Dis. 2016; 34: 11-18
        View in Article
        • Wang Z.
        • Roberts A.B.
        • Buffa J.A.
        • Levison B.S.
        • Zhu W.
        • Org E.
        • et al.
        Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis.
        Cell. 2015; 163: 1585-1595
        View in Article
        • Adolph T.E.
        • Grander C.
        • Grabherr F.
        • Tilg H.
        Adipokines and non-alcoholic fatty liver disease: multiple interactions.
        Int J Mol Sci. 2017; 18
        View in Article

      Article info

      Publication history

      Published online: December 10, 2017
      Accepted: December 4, 2017
      Received: December 3, 2017
      See Article, pages 764–772

      Identification

      DOI: https://doi.org/10.1016/j.jhep.2017.12.002

      Copyright

      © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX